Perioperative use of intra-articular steroids during the COVID-19 pandemic
Purpose There are growing concerns with the widely used glucocorticoids during the Coronavirus disease-19 (COVID-19) pandemic due to the associated immunosuppressive effects, which may increase the risk of COVID-19 infection and worsen COVID-19 patient outcome. Heavily affecting orthopaedics, the pandemic led to delay and cancellation of almost all surgical cases, and procedures including perioperative intra-articular corticosteroid injections (ICIs) saw similar decreases. However, the benefits of ICI treatments during the pandemic may outweigh these potential risks, and their continued use may be warranted. Methods A literature search was conducted, and all relevant articles including original articles and reviews were identified and considered in full for inclusion, and analysed with expert opinion. Epidemiological statistics and medical guidelines were consulted from relevant authorities. Results ICIs allow a targeted approach on the affected joint and are effective in reducing pain while improving functional outcome and patient quality-of-life. ICIs delay the requirement for surgery, accommodating for the increased healthcare burden during the pandemic, while reducing postoperative hospital stay, bringing significant financial benefits. However, ICIs can exert systemic effects and suppress the immune system. ICIs may increase the risk of COVID-19 infection and reduce the efficacy of COVID-19 vaccinations, leading to important public health implications. Conclusion Perioperative ICI treatments may bring significant, multifaceted benefits during the pandemic. However, ICIs increase the risk of infection, and perioperative COVID-19 is associated with mortality. The use of ICIs during the COVID-19 pandemic should therefore be considered carefully on an individual patient basis, weighing the associated risks and benefits..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
European journal of orthopaedic surgery & traumatology - 32(2021), 7 vom: 01. Sept., Seite 1225-1235 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jou, Eric [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
© The Author(s) 2021 |
|---|
| doi: |
10.1007/s00590-021-03105-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR04799083X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR04799083X | ||
| 003 | DE-627 | ||
| 005 | 20230519235711.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220901s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00590-021-03105-x |2 doi | |
| 035 | |a (DE-627)SPR04799083X | ||
| 035 | |a (SPR)s00590-021-03105-x-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jou, Eric |e verfasserin |0 (orcid)0000-0002-6259-4874 |4 aut | |
| 245 | 1 | 0 | |a Perioperative use of intra-articular steroids during the COVID-19 pandemic |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2021 | ||
| 520 | |a Purpose There are growing concerns with the widely used glucocorticoids during the Coronavirus disease-19 (COVID-19) pandemic due to the associated immunosuppressive effects, which may increase the risk of COVID-19 infection and worsen COVID-19 patient outcome. Heavily affecting orthopaedics, the pandemic led to delay and cancellation of almost all surgical cases, and procedures including perioperative intra-articular corticosteroid injections (ICIs) saw similar decreases. However, the benefits of ICI treatments during the pandemic may outweigh these potential risks, and their continued use may be warranted. Methods A literature search was conducted, and all relevant articles including original articles and reviews were identified and considered in full for inclusion, and analysed with expert opinion. Epidemiological statistics and medical guidelines were consulted from relevant authorities. Results ICIs allow a targeted approach on the affected joint and are effective in reducing pain while improving functional outcome and patient quality-of-life. ICIs delay the requirement for surgery, accommodating for the increased healthcare burden during the pandemic, while reducing postoperative hospital stay, bringing significant financial benefits. However, ICIs can exert systemic effects and suppress the immune system. ICIs may increase the risk of COVID-19 infection and reduce the efficacy of COVID-19 vaccinations, leading to important public health implications. Conclusion Perioperative ICI treatments may bring significant, multifaceted benefits during the pandemic. However, ICIs increase the risk of infection, and perioperative COVID-19 is associated with mortality. The use of ICIs during the COVID-19 pandemic should therefore be considered carefully on an individual patient basis, weighing the associated risks and benefits. | ||
| 650 | 4 | |a Injections |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Intra-articular |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Perioperative period |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Steroids |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SARS-CoV-2 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Pandemics |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Zhou, Andrew Kailin |4 aut | |
| 700 | 1 | |a Ho, Jamie Sin Ying |4 aut | |
| 700 | 1 | |a Thahir, Azeem |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of orthopaedic surgery & traumatology |d Paris : Springer France, 1991 |g 32(2021), 7 vom: 01. Sept., Seite 1225-1235 |w (DE-627)SPR006945333 |w (DE-600)1478935-8 |x 1432-1068 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2021 |g number:7 |g day:01 |g month:09 |g pages:1225-1235 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00590-021-03105-x |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2021 |e 7 |b 01 |c 09 |h 1225-1235 | ||